Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Contemporary drug synthesis / / Jie Jack Li [et al.]
| Contemporary drug synthesis / / Jie Jack Li [et al.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Design |
| ISBN |
1-280-27291-0
9786610272914 0-470-23708-2 0-471-68673-5 0-471-68674-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNINA-9910146084303321 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Contemporary drug synthesis / / Jie Jack Li [et al.]
| Contemporary drug synthesis / / Jie Jack Li [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J. : , : Wiley-Interscience, , 2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico |
Pharmaceutical chemistry
Drugs - Design |
| ISBN |
1-280-27291-0
9786610272914 0-470-23708-2 0-471-68673-5 0-471-68674-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNISA-996211665003316 |
| Hoboken, N.J. : , : Wiley-Interscience, , 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Contemporary drug synthesis / / Jie Jack Li ... [et al.]
| Contemporary drug synthesis / / Jie Jack Li ... [et al.] |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, c2004 |
| Descrizione fisica | 1 online resource (xv, 221 pages) : illustrations |
| Disciplina | 615/.31 |
| Altri autori (Persone) | LiJie Jack |
| Soggetto topico | Pharmaceutical chemistry |
| ISBN |
9786610272914
9781280272912 1280272910 9780470237083 0470237082 9780471686736 0471686735 9780471686743 0471686743 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contemporary Drug Synthesis; Preface; Table of Contents; Trade Names and Their Corresponding USANs; Acronyms and Abbreviations; Chapter 1: Antithrombotics: Ticlopidine (Ticlid® and Clopidogrel (Plavix®); 1 .1 Introduction; 1.2 Syntheses of ticlopidine; 1.3 Syntheses of clopidogrel; 1.4 References; Chapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex®) and Rofecoxib (Vioxx®); 2.1 Introduction; 2.2 Synthesis of celecoxib; 2.3 Syntheses of rofecoxib; 2.4 References; Chapter 3. H+/K+-ATPase Inhibitors: Esomeprazole (Nexium®); 3.1 Introduction
3.2 Synthesis of esomeprazole; 3.2.1 Separation using HPLC; 3.2.2 Asymmetric oxidation of the sulfide; 3.2.3 Biooxidation; 3.3 References; Chapter 4. Protein-tyrosine Kinase Inhibitors: Imatinib (Gleevec®) and Gefitinib (Iressa®); 4.1 Introduction to Gleevec®; 4.2 Synthesis of imatinib mesylate; 4.3 Introduction to Iressa®; 4.4 Synthesis of gefitinib; 4.5 References; Chapter 5. Non-sedating Antihistamines; 5.1 Introduction; 5.2 Synthesis of loratadine and desloratadine; 5.3 Synthesis of fexofenadine; 5.4 Synthesis of cetirizine; 5.5 References Chapter 6. Cosmeceuticals: Isotretinoin (Accutane®), Tazarotene (Tazorac®), Minoxidil (Rogaine®), and Finasteride (Propecia®); 6.1 Isotretinoin; 6.1.1 Introduction to isotretinoin; 6.1.2 Synthesis of isotretinoin; 6.2 Tazarotene; 6.2.1 Introduction to tazarotene; 6.2.2 Synthesis of tazarotene; 6.3 Minoxidil; 6.3.1 Introduction to minoxidil; 6.3.2 Synthesis of minoxidil; 6.4 Finasteride; 6.4.1 Introduction to finasteride; 6.4.2 Synthesis of finasteride; 6.5 References; Chapter 7. Antibacterials: Ciprofloxacin (Cipro®) and Linezolid (Zyvox®); 7.1 Ciprofloxacin (Cipro®) 7.1.1 Introduction to ciprofloxacin 7.1.2 Synthesis of ciprofloxacin; 7.2 Linezolid (Zyvox®); 7.2.1 Introduction to linezolid; 7.2.2 Synthesis of linezolid; 7.3 References; Chapter 8. Atypical Antipsychotics; 8.1 Introduction; 8.2 Synthesis of risperidone; 8.3 Synthesis of olanzapine; 8.4 Synthesis of quetiapine fumarate; 8.5 Synthesis of ziprasidone; 8.6 Synthesis of aripiprazole; 8.7 References; Chapter 9. Atorvastatin Calcium (Lipitor®); 9.1 Background; 9.2 Synthesis of racemic atorvastatin; 9.3 Enantioselective syntheses of atorvastatin calcium; 9.4 References Chapter 10. Antidepressants; 10.1 Background; 10.2 Synthesis of fluoxetine hydrochloride; 10.3 Synthesis of sertraline hydrochloride; 10.4 Synthesis of paroxetine hydrochloride; 10.5 References; Chapter 11. Anti-obesity: Orlistat (Xenical®); 11.1 Introduction; 11.2 Synthesis of orlistat; 11.3 References; Chapter 12. Triptans for Migraine; 12.1 Introduction; 12.2 Synthesis of sumatriptan; 12.3 Synthesis of zolmitriptan; 12.4 Synthesis of naratriptan; 12.5 Synthesis of rizatriptan; 12.6 Synthesis of almotriptan; 12.7 Synthesis of frovatriptan; 12.8 Synthesis of eletriptan; 12.9 References |
| Record Nr. | UNINA-9910818441403321 |
| Hoboken, N.J., : Wiley-Interscience, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Oligonucleotides as therapeutic agents / / [editors, Derek J. Chadwick (Organizer) and Gail Cardew]
| Oligonucleotides as therapeutic agents / / [editors, Derek J. Chadwick (Organizer) and Gail Cardew] |
| Pubbl/distr/stampa | Chichester ; ; New York, : Wiley, 1997 |
| Descrizione fisica | 1 online resource (262 p.) |
| Disciplina | 615/.31 |
| Altri autori (Persone) |
ChadwickDerek
CardewGail |
| Collana | Ciba Foundation symposium |
| Soggetto topico |
Oligonucleotides - Therapeutic use
Antisense nucleic acids - Therapeutic use |
| ISBN |
9786612348051
9781282348059 1282348051 9780470515396 0470515392 9780470515402 0470515406 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS; Contents; Participants; Introduction; Oligoncleotide analogues: an overview; Phosphorothioate oligodeox ynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry; Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays; Pharrnacokinetics of oligonucleotides in cell culture; Pharrnacokinetics of oligonucleotides; Controversies in the cellular pharmacology of oligodeox ynucleotides; Sequence-specific control of gene expression by antigene and clamp oligonucleotides
First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinaseDifferential oligonucleotide activity in cell culture versus mouse models; Structure-activity relationships in cell culture; Progress in antisense therapeutics discovery and development; Oligonucleotide therapeutics for human leukemia; Therapeutic applications of catalytic antisense RNAs (ribozymes); Exogenous application of riboaymes for inhibiting gene expression; Efficient process technologies for the preparation of oligonucleotides In vivo production of oligodeoxyribonucleotides of specific sequences: application to antisense DNASummary; Index of contributors; Subject index |
| Record Nr. | UNINA-9911019931203321 |
| Chichester ; ; New York, : Wiley, 1997 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Synthetic multivalent molecules [[electronic resource] ] : concepts and biomedical applications / / Seok-ki Choi
| Synthetic multivalent molecules [[electronic resource] ] : concepts and biomedical applications / / Seok-ki Choi |
| Autore | Choi Seok-ki <1964-> |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2004 |
| Descrizione fisica | 1 online resource (446 p.) |
| Disciplina |
615.31
615/.31 |
| Soggetto topico |
Multivalent molecules - Synthesis
Multivalent molecules - Design Multivalent molecules - Physiological effect |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-280-54191-1
9786610541911 0-471-57770-7 0-471-57890-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYNTHETIC MULTIVALENT MOLECULES; CONTENTS; Preface; Notes for Organization and Classification; Abbreviations; 1 Introduction; 1.1 Nomenclature and Definitions; 1.1.1 Valency; 1.1.2 Linkers; 1.1.3 Scaffolds; 1.1.4 Ligand Density; 1.1.5 Homo- and Heterovalent Molecules; 1.2 Mechanistic Aspects of Multivalent Interaction; 1.2.1 Affinity Constant and Avidity; 1.2.2 Thermodynamics; 1.2.3 Kinetics; 1.2.4 Steric Effects; 1.3 Biological Roles of Multivalent Ligands; 2 Multivalent Molecules Applied to Viral Targets; 2.1 Influenza Virus; 2.1.1 Hemagglutinin; 2.1.1.1 Divalent Sialic Acid
2.1.1.2 Tetravalent Sialoside2.1.1.3 Dendrimers Presenting Sialosides; 2.1.1.4 Sialic Acid Displayed in Liposomes; 2.1.1.5 Polymerized Liposome Presenting Sialic Acid; 2.1.1.6 Sialic Acid in Langmuir-Blodget Monolayers; 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces; 2.1.1.8 Poly(acrylamide) Presenting Sialosides; 2.1.1.9 Poly(acrylic acid) Presenting Sialosides; 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides; 2.1.1.11 Postmodification of Activated Polymers; 2.1.1.12 Modes of Action of Polymeric Sialosides; 2.1.1.13 OPTCOL Assay; 2.1.1.14 ter-Poly(acrylic acid) Presenting Sialosides 2.1.1.15 Poly(glutamic acid) Presenting Lysogangliosides2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid-Containing Trisaccharides; 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C(4) Position; 2.1.1.18 Poly(acrylamide) Tethering 9-O-Acetylsialosides; 2.1.1.19 Neoglycoprotein Displaying Sialic Acids; 2.1.1.20 Natural b-Inhibitors; 2.1.2 Neuraminidase; 2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors; 2.2 Human Immunodeficiency Virus; 2.2.1 HIV-1 Protease; 2.2.1.1 Divalent Terminal Peptides; 2.2.2 HIV-1 Reverse Transcriptase; 2.2.2.1 Heterodimers Composed of NRTI and NNRTI 2.2.3 Glycoprotein 120 (gp120) on Viral Surfaces2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide; 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces; 2.2.3.3 Multivalent Anions; 2.2.3.4 Bivalent Antagonists of CXCR4; 2.2.4 Surface Carbohydrates on HIV; 2.2.4.1 Oligomannose Sugars Present on gp120; 2.2.4.2 Modes of CVN Recognition; 2.3 Rotavirus; 2.4 Polyoma Virus; 2.5 Picorna Virus; 2.6 Respiratory Syncytial Virus; 2.7 Dengue Virus; 2.8 Nucleic Acids of Viruses; 2.8.1 RNA-Protein Interactions; 2.8.1.1 Neomycin B Linked to Acridine; 2.8.1.2 Neamine Linked to Pyrene-Carboxylic Acid 2.8.2 RNA-Enzyme Interactions2.8.3 Binders to the Minor Groove of Viral DNA; 2.8.3.1 Hairpin-Shaped Polyamide Dimers; 2.8.3.2 H-Shaped Polyamide Dimers; 2.8.3.3 Naturally Occurring Dimers; 2.9 Synthetic Multivalent Vaccines; 2.9.1 Peptide-Based Anti-influenza Vaccines; 2.9.2 Gp41-Based Anti-HIV Vaccine; 2.9.3 Peptide-Based Anti-FMDV Vaccines; 3 Multivalent Molecules Applied to Bacterial Targets; 3.1 Targets in Bacterial Cell Membranes; 3.1.1 D-Ala-D-Ala Peptide Precursors; 3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class; 3.1.1.2 Dimerization of Glycopeptide Antibiotics 3.1.1.3 Di- and Trivalent Vancomycin |
| Record Nr. | UNINA-9910146077703321 |
Choi Seok-ki <1964->
|
||
| Hoboken, N.J., : Wiley, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Synthetic multivalent molecules [[electronic resource] ] : concepts and biomedical applications / / Seok-ki Choi
| Synthetic multivalent molecules [[electronic resource] ] : concepts and biomedical applications / / Seok-ki Choi |
| Autore | Choi Seok-ki <1964-> |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2004 |
| Descrizione fisica | 1 online resource (446 p.) |
| Disciplina |
615.31
615/.31 |
| Soggetto topico |
Multivalent molecules - Synthesis
Multivalent molecules - Design Multivalent molecules - Physiological effect |
| ISBN |
1-280-54191-1
9786610541911 0-471-57770-7 0-471-57890-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYNTHETIC MULTIVALENT MOLECULES; CONTENTS; Preface; Notes for Organization and Classification; Abbreviations; 1 Introduction; 1.1 Nomenclature and Definitions; 1.1.1 Valency; 1.1.2 Linkers; 1.1.3 Scaffolds; 1.1.4 Ligand Density; 1.1.5 Homo- and Heterovalent Molecules; 1.2 Mechanistic Aspects of Multivalent Interaction; 1.2.1 Affinity Constant and Avidity; 1.2.2 Thermodynamics; 1.2.3 Kinetics; 1.2.4 Steric Effects; 1.3 Biological Roles of Multivalent Ligands; 2 Multivalent Molecules Applied to Viral Targets; 2.1 Influenza Virus; 2.1.1 Hemagglutinin; 2.1.1.1 Divalent Sialic Acid
2.1.1.2 Tetravalent Sialoside2.1.1.3 Dendrimers Presenting Sialosides; 2.1.1.4 Sialic Acid Displayed in Liposomes; 2.1.1.5 Polymerized Liposome Presenting Sialic Acid; 2.1.1.6 Sialic Acid in Langmuir-Blodget Monolayers; 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces; 2.1.1.8 Poly(acrylamide) Presenting Sialosides; 2.1.1.9 Poly(acrylic acid) Presenting Sialosides; 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides; 2.1.1.11 Postmodification of Activated Polymers; 2.1.1.12 Modes of Action of Polymeric Sialosides; 2.1.1.13 OPTCOL Assay; 2.1.1.14 ter-Poly(acrylic acid) Presenting Sialosides 2.1.1.15 Poly(glutamic acid) Presenting Lysogangliosides2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid-Containing Trisaccharides; 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C(4) Position; 2.1.1.18 Poly(acrylamide) Tethering 9-O-Acetylsialosides; 2.1.1.19 Neoglycoprotein Displaying Sialic Acids; 2.1.1.20 Natural b-Inhibitors; 2.1.2 Neuraminidase; 2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors; 2.2 Human Immunodeficiency Virus; 2.2.1 HIV-1 Protease; 2.2.1.1 Divalent Terminal Peptides; 2.2.2 HIV-1 Reverse Transcriptase; 2.2.2.1 Heterodimers Composed of NRTI and NNRTI 2.2.3 Glycoprotein 120 (gp120) on Viral Surfaces2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide; 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces; 2.2.3.3 Multivalent Anions; 2.2.3.4 Bivalent Antagonists of CXCR4; 2.2.4 Surface Carbohydrates on HIV; 2.2.4.1 Oligomannose Sugars Present on gp120; 2.2.4.2 Modes of CVN Recognition; 2.3 Rotavirus; 2.4 Polyoma Virus; 2.5 Picorna Virus; 2.6 Respiratory Syncytial Virus; 2.7 Dengue Virus; 2.8 Nucleic Acids of Viruses; 2.8.1 RNA-Protein Interactions; 2.8.1.1 Neomycin B Linked to Acridine; 2.8.1.2 Neamine Linked to Pyrene-Carboxylic Acid 2.8.2 RNA-Enzyme Interactions2.8.3 Binders to the Minor Groove of Viral DNA; 2.8.3.1 Hairpin-Shaped Polyamide Dimers; 2.8.3.2 H-Shaped Polyamide Dimers; 2.8.3.3 Naturally Occurring Dimers; 2.9 Synthetic Multivalent Vaccines; 2.9.1 Peptide-Based Anti-influenza Vaccines; 2.9.2 Gp41-Based Anti-HIV Vaccine; 2.9.3 Peptide-Based Anti-FMDV Vaccines; 3 Multivalent Molecules Applied to Bacterial Targets; 3.1 Targets in Bacterial Cell Membranes; 3.1.1 D-Ala-D-Ala Peptide Precursors; 3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class; 3.1.1.2 Dimerization of Glycopeptide Antibiotics 3.1.1.3 Di- and Trivalent Vancomycin |
| Record Nr. | UNINA-9910830426003321 |
|
Choi Seok-ki <1964->
|
||
| Hoboken, N.J., : Wiley, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Synthetic multivalent molecules : concepts and biomedical applications / / Seok-ki Choi
| Synthetic multivalent molecules : concepts and biomedical applications / / Seok-ki Choi |
| Autore | Choi Seok-ki <1964-> |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2004 |
| Descrizione fisica | 1 online resource (446 p.) |
| Disciplina | 615/.31 |
| Soggetto topico |
Multivalent molecules - Synthesis
Multivalent molecules - Design Multivalent molecules - Physiological effect |
| ISBN |
9786610541911
9781280541919 1280541911 9780471577706 0471577707 9780471578901 0471578908 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
SYNTHETIC MULTIVALENT MOLECULES; CONTENTS; Preface; Notes for Organization and Classification; Abbreviations; 1 Introduction; 1.1 Nomenclature and Definitions; 1.1.1 Valency; 1.1.2 Linkers; 1.1.3 Scaffolds; 1.1.4 Ligand Density; 1.1.5 Homo- and Heterovalent Molecules; 1.2 Mechanistic Aspects of Multivalent Interaction; 1.2.1 Affinity Constant and Avidity; 1.2.2 Thermodynamics; 1.2.3 Kinetics; 1.2.4 Steric Effects; 1.3 Biological Roles of Multivalent Ligands; 2 Multivalent Molecules Applied to Viral Targets; 2.1 Influenza Virus; 2.1.1 Hemagglutinin; 2.1.1.1 Divalent Sialic Acid
2.1.1.2 Tetravalent Sialoside2.1.1.3 Dendrimers Presenting Sialosides; 2.1.1.4 Sialic Acid Displayed in Liposomes; 2.1.1.5 Polymerized Liposome Presenting Sialic Acid; 2.1.1.6 Sialic Acid in Langmuir-Blodget Monolayers; 2.1.1.7 Sialic Acid Presented on Biopolymer Surfaces; 2.1.1.8 Poly(acrylamide) Presenting Sialosides; 2.1.1.9 Poly(acrylic acid) Presenting Sialosides; 2.1.1.10 Poly(acrylamide) Presenting C-Sialosides; 2.1.1.11 Postmodification of Activated Polymers; 2.1.1.12 Modes of Action of Polymeric Sialosides; 2.1.1.13 OPTCOL Assay; 2.1.1.14 ter-Poly(acrylic acid) Presenting Sialosides 2.1.1.15 Poly(glutamic acid) Presenting Lysogangliosides2.1.1.16 Poly(glutamic acid) Bearing Sialic Acid-Containing Trisaccharides; 2.1.1.17 Poly(acrylamide) Bearing Sialic Acid Linked at the C(4) Position; 2.1.1.18 Poly(acrylamide) Tethering 9-O-Acetylsialosides; 2.1.1.19 Neoglycoprotein Displaying Sialic Acids; 2.1.1.20 Natural b-Inhibitors; 2.1.2 Neuraminidase; 2.1.2.1 Poly(glutamic acid) Presenting NA Inhibitors; 2.2 Human Immunodeficiency Virus; 2.2.1 HIV-1 Protease; 2.2.1.1 Divalent Terminal Peptides; 2.2.2 HIV-1 Reverse Transcriptase; 2.2.2.1 Heterodimers Composed of NRTI and NNRTI 2.2.3 Glycoprotein 120 (gp120) on Viral Surfaces2.2.3.1 Neoglycoprotein-Displaying CD4 Peptide; 2.2.3.2 Galactosyl Ceramide Immobilized on Viral Surfaces; 2.2.3.3 Multivalent Anions; 2.2.3.4 Bivalent Antagonists of CXCR4; 2.2.4 Surface Carbohydrates on HIV; 2.2.4.1 Oligomannose Sugars Present on gp120; 2.2.4.2 Modes of CVN Recognition; 2.3 Rotavirus; 2.4 Polyoma Virus; 2.5 Picorna Virus; 2.6 Respiratory Syncytial Virus; 2.7 Dengue Virus; 2.8 Nucleic Acids of Viruses; 2.8.1 RNA-Protein Interactions; 2.8.1.1 Neomycin B Linked to Acridine; 2.8.1.2 Neamine Linked to Pyrene-Carboxylic Acid 2.8.2 RNA-Enzyme Interactions2.8.3 Binders to the Minor Groove of Viral DNA; 2.8.3.1 Hairpin-Shaped Polyamide Dimers; 2.8.3.2 H-Shaped Polyamide Dimers; 2.8.3.3 Naturally Occurring Dimers; 2.9 Synthetic Multivalent Vaccines; 2.9.1 Peptide-Based Anti-influenza Vaccines; 2.9.2 Gp41-Based Anti-HIV Vaccine; 2.9.3 Peptide-Based Anti-FMDV Vaccines; 3 Multivalent Molecules Applied to Bacterial Targets; 3.1 Targets in Bacterial Cell Membranes; 3.1.1 D-Ala-D-Ala Peptide Precursors; 3.1.1.1 Mode of Action by Antibiotics of the Vancomycin Class; 3.1.1.2 Dimerization of Glycopeptide Antibiotics 3.1.1.3 Di- and Trivalent Vancomycin |
| Record Nr. | UNINA-9911019559303321 |
|
Choi Seok-ki <1964->
|
||
| Hoboken, N.J., : Wiley, c2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||